2026-02-24
GLP-1 Agonists and Aging: Metabolic Benefits, Cardiovascular Evidence, and Longevity Implications
GLP-1 receptor agonists like semaglutide have demonstrated cardiovascular and metabolic benefits beyond weight reduction. This review covers the mechanistic basis, major trial evidence, and the open questions about their role in longevity medicine.
2026-02-24
Grip Strength as a Longevity Biomarker: Evidence and Interventions
Grip strength is one of the most powerful and accessible biomarkers of biological aging, predicting cardiovascular events, hospitalization, and all-cause mortality more reliably than many clinical tests. This article covers the mechanisms, evidence, and interventions.
2026-02-24
Kidney Health and Aging: GFR Decline, Protein Intake, and Renoprotective Strategies
GFR declines ~1 mL/min/year after age 40. In early-stage CKD, protein restriction, blood pressure control, and avoiding nephrotoxic supplements (high-dose oxalate, aristolochic acid) are the primary levers. Potassium citrate and omega-3 have supportive evidence.
2026-02-24
Longevity Biomarkers: What to Test, What the Results Mean, and How to Track Progress
Biological age testing spans conventional labs (HbA1c, CRP, lipids) to newer epigenetic clocks and proteomic aging scores. Most conventional biomarkers are actionable today; epigenetic clocks measure biological vs. chronological age but their clinical utility for intervention-guiding remains limited. A pragmatic panel of validated tests provides meaningful signal about longevity trajectory.
2026-02-24
Sodium-Potassium Balance in Aging: The Dietary Lever for Blood Pressure and Vascular Health
The ratio of dietary sodium to potassium is a more powerful predictor of cardiovascular risk than sodium intake alone. This article reviews the evidence for the Na/K balance as a therapeutic target and practical approaches to correction.